<DOC>
	<DOCNO>NCT00091572</DOCNO>
	<brief_summary>The purpose study ascertain extend schedule Temozolomide , allow increase dos potential depletion enzyme underlay resistance , effective treatment metastatic melanoma single agent dacarbazine .</brief_summary>
	<brief_title>Temozolomide Versus Dacarbazine Stage IV Metastatic Melanoma ( Study P03267 )</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Histologically confirm , stage IV , surgically incurable melanoma Age 18 year old World Health Organization ( WHO ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Meets protocol requirement specify laboratory value Must able take oral medication Must disease free cancer period 5 year ( except surgically cure carcinoma insitu cervix basal squamous cell carcinoma skin ) . Women childbearing potential men must practice medically approve contraception . Must provide write informedconsent participate study . Must full recovery major surgery adjuvant treatment No clinically uncontrolled infectious disease include HIV AIDSrelated illness Ocular melanoma Brain Metastases Prior cytokine chemotherapy stage IV disease Pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Metastatic Melanoma</keyword>
</DOC>